Hexarelin Side Effects

Reported Hexarelin side effects

Common Facial flushing and warmth — More pronounced than other GHRPs. Fades within 15-30 minutes. Injection site reactions — Mild erythema, occasional stinging at SC site. Site rotation minimizes. Cortisol elevation (significant after a 2 mcg/kg IV dose, PMID 7586608; similar with GHRP-2 at the same dose, PMID 10195374) — Transient, peaks 60-90 min post-injection, resolves by 3-4 hours. In healthy users with normal HPA function, typically clinically inconsequential per single dose; cumulative chronic exposure matters more. Prolactin elevation — Usually modest; GHRP-2 at the same intravenous dose raised prolactin to a similar level in young adults (Arvat et al., 1999), and no human study has compared hexarelin with ipamorelin. Relevant in users with prolactin-sensitive conditions. Appetite stimulation — Intermediate; noticeable but less pronounced than GHRP-6. Vivid dreams — Common with bedtime dosing. Less Common Headache — More frequent than with other GHRPs, particularly in first week. Mild nausea — More common with higher doses or IV administration. Transient hypotension — Primarily with rapid IV bolus; SC route rarely produces meaningful BP changes. Fluid retention — Mild, most pronounced in first 2-3 weeks of daily use. Insulin sensitivity reduction — Measurable with chronic dosing; monitor HbA1c and fasting insulin. Paresthesia / scalp tingling — Transient, benign. HPA Axis Effects ACTH elevation — Meaningful and measurable; GHRP-2 at the same intravenous dose raised ACTH to a similar level in young adults (Arvat et al., 1999) Cumulative cortisol exposure with chronic daily dosing could theoretically contribute to HPA dysregulation over months Patients with anxiety, cortisol-sensitive mood disorders, or adrenal insufficiency are poor candidates for hexarelin Receptor Desensitization GH response attenuation within 4-8 weeks of continuous daily dosing Dose escalation to overcome attenuation increases cortisol and prolactin exposure disproportionately Shorter cycling (4-6 weeks on / 2-4 weeks off) is standard for this compound specifically Rare but Notable Significant hypotension — primarily with IV; rare with SC Hypersensitivity reactions — rare local or systemic Persistent insulin resistance — with prolonged high-dose use HPA axis blunting — theoretical concern with long-term continuous dosing Long-term Theoretical Concerns As with all GH-axis interventions, sustained IGF-1 elevation raises theoretical concerns around chronic mitogenic signaling and cancer risk. Hexarelin's HPA axis effects add an additional concern — chronic low-grade cortisol elevation has independent metabolic consequences (visceral fat accumulation, insulin resistance, immune suppression) that compound over long timescales. Short-cycle use minimizes this risk significantly. Signs You Are Overdosing or Need to Stop Persistent joint pain, peripheral edema, or carpal tunnel symptoms (IGF-1 too high) Fasting glucose persistently >110 mg/dL Mood changes, insomnia, or anxiety (HPA axis effects) Central weight gain or Cushing-like body composition changes Persistent elevated resting heart rate Worsening sleep apnea Any cardiovascular symptoms

When to continue, reduce, or stop Hexarelin

Hexarelin contraindications

Hexarelin is contraindicated or requires strict caution in: Active malignancy — particularly hormone-responsive cancers; IGF-1 elevation theoretical risk Strong family history of GH-axis sensitive cancers — specialist supervision required Pregnancy and lactation — no established safety data Known hypersensitivity to hexarelin or related hexapeptides Severe untreated obstructive sleep apnea — stabilize with CPAP first Acute critical illness — GH-axis stimulation inappropriate during sepsis, post-surgical recovery, multiple trauma, respiratory failure Diabetic ketoacidosis or severe uncontrolled diabetes — resolve metabolic state first Active proliferative retinopathy — relative contraindication Hypothalamic-pituitary disease with untreated adrenal insufficiency — hexarelin's HPA effects may be unreliable in this context Active Cushing's syndrome or elevated baseline cortisol — hexarelin adds meaningfully to HPA load Prolactinoma or clinically significant hyperprolactinemia — hexarelin's prolactin elevation could complicate management Active anxiety disorder, panic disorder, or acute stress reaction — HPA axis effects can worsen symptoms Relative cautions specific to hexarelin: Borderline glucose / HbA1c — insulin sensitivity effects appear faster with hexarelin than with cleaner GHS compounds Mood instability, depression, or insomnia — the HPA axis effects may contribute to worsening Cardiovascular disease (despite preclinical CD36 data) — the acute blood pressure and cortisol effects are not neutral in this population; clinical cardiac use has not been validated Concurrent glucocorticoid therapy — pharmacodynamic interference; additive HPA load Strong family history of colon polyps — baseline colonoscopy before GH-axis intervention Users who have had previous difficulty tolerating GHS compounds — hexarelin raises ACTH, cortisol and prolactin about as much as GHRP-2 at the same dose (PMID 10195374), and the evidence that ipamorelin spares these hormones comes only from swine (PMID 9849822) Drug interactions: Glucocorticoids: Reduced GH response; additive HPA load Stimulants (high caffeine, pre-workouts): Additive sympathomimetic and HPA load MAO inhibitors: Theoretical interaction; specialist oversight GLP-1 agonists during weight loss phase: Opposing appetite signals Thyroid hormones: GH-axis effects can alter thyroid needs Exogenous HGH: Pharmacologically counterproductive Discontinuation triggers: Cortisol elevation >30% above baseline at follow-up labs ACTH elevation beyond reference range Prolactin elevation beyond reference range New or worsened anxiety, insomnia, or mood changes Fasting glucose persistently >110 mg/dL Central (abdominal) weight gain beyond caloric intake explanation — suggesting cortisol-driven body composition change Persistent joint pain or peripheral edema Worsening sleep apnea Any cardiovascular symptoms

Why vendor quality drives Hexarelin side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Hexarelin side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .